/OTLC
OTLC Stock - Oncotelic Therapeutics, Inc.
Healthcare|BiotechnologyOTC
$0.09+0.56%
+$0.00 (+0.56%) • Dec 19
72
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.70
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.10
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for OTLC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.09 – $0.09
TARGET (TP)$0.10
STOP LOSS$0.08
RISK/REWARD1:1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.76
52W High$0.11
52W Low$0.02
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $70,000 | N/A | N/A | $1.74M |
| Gross Profit | N/A | $70,000 | $-12,841 | $-61,513 | $1.74M |
| Gross Margin | N/A | 100.0% | N/A | N/A | 100.0% |
| Operating Income | $-3,576,013,000 | $-6,648,015 | $-9,721,653 | $-9,125,883 | $-7,584,734 |
| Net Income | $-4,523,932,000 | $-7,903,093 | $17.82M | $-11,393,855 | $-11,500,923 |
| Net Margin | N/A | -11290.1% | N/A | N/A | -660.6% |
| EPS | $-0.01 | $-0.02 | $0.05 | $-0.04 | $-0.13 |
Company Overview
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
OTLCBeat Rate
25%
Last 4 quarters
Avg Surprise
-49.6%
EPS vs Estimate
Beats / Misses
1/3
Last 12 quarters
Latest EPS
$-0.00
Q4 2025
EPS Surprise History
Q2 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q2 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q4 2025 | Nov 17, 2025 | — | $-0.00 | — | — |
Q3 2025 | Aug 13, 2025 | — | $0.00 | — | — |
Q2 2025 | May 15, 2025 | — | $-0.00 | — | — |
Q2 2025 | Apr 15, 2025 | — | $-0.00 | — | — |
Q4 2024 | Nov 19, 2024 | — | $-0.01 | — | — |
Q3 2024 | Aug 14, 2024 | — | $-0.00 | — | — |
Q2 2024 | Apr 15, 2024 | — | $-0.00 | — | — |
Q2 2024 | Apr 12, 2024 | — | $-0.00 | — | — |
Q4 2023 | Nov 14, 2023 | — | $0.00 | — | — |
Q3 2023 | Aug 18, 2023 | — | $-0.02 | — | — |
Q2 2023 | Apr 17, 2023 | — | $-0.01 | — | — |
Q2 2023 | Apr 14, 2023 | — | $-0.01 | — | — |
Q4 2022 | Nov 21, 2022 | — | $-0.00 | — | — |
Q3 2022 | Aug 22, 2022 | — | $0.04 | — | — |
Q2 2022 | May 23, 2022 | $-0.01 | $-0.01 | -100.0% | ✗ MISS |
Q2 2022 | Apr 18, 2022 | $-0.01 | $-0.00 | +51.6% | ✓ BEAT |
Q4 2021 | Nov 22, 2021 | $-0.00 | $-0.00 | -100.0% | ✗ MISS |
Q3 2021 | Aug 20, 2021 | — | $-0.01 | — | — |
Q2 2021 | May 24, 2021 | $-0.02 | $-0.03 | -50.0% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about OTLC
What is OTLC's current stock price?
Oncotelic Therapeutics, Inc. (OTLC) is currently trading at $0.09 per share. The stock has moved +0.56% today.
What is the analyst price target for OTLC?
No analyst price targets are currently available for this stock.
What sector is Oncotelic Therapeutics, Inc. in?
Oncotelic Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is OTLC's market cap?
Oncotelic Therapeutics, Inc. has a market capitalization of $0.04 billion, making it a small-cap company.
Does OTLC pay dividends?
No, Oncotelic Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACHFF
Arch Biopartners Inc.
$0.89
Mkt Cap: $0.1B
BLOZF
Cannabix Technologies Inc.
$0.41
Mkt Cap: $0.0B
CVALF
Covalon Technologies Ltd.
$1.25
Mkt Cap: $0.0B
CXXIF
C21 Investments Inc.
$0.32
Mkt Cap: $0.0B
HBPCF
Helix BioPharma Corp.
$1.73
Mkt Cap: $0.1B
INNMF
Amplia Therapeutics Limited
$0.08
Mkt Cap: $0.0B
PSYBF
PsyBio Therapeutics Corp.
$0.00
Mkt Cap: $0.0B
RLFTF
Relief Therapeutics Holding AG
$2.70
Mkt Cap: $0.0B
RLFTY
MindMaze Therapeutics Holding S.A. Sponsored ADR
$3.65
Mkt Cap: $0.0B
ZIVO
ZIVO Bioscience, Inc.
$9.98
Mkt Cap: $0.0B
Explore stocks similar to OTLC for comparison